Claims for Patent: 5,874,405

Summary for Patent: 5,874,405

Title:	Heat shock protein peptides that share sequences with cyclic nucleotide phosphodiesterase and methods for modulating autoimmune central nervous system disease
Abstract:	The invention provides for peptides and methods of using peptides to block or inhibit a pathogenic autoimmune response to central nervous system components. The peptides are antigens derived from mycobacterial heat shock proteins and that immunologically crossreact with or are homologous to myelin components. The peptides can also be derived from myelin components such as 2\',3\' cyclic nucleotide phosphodiesterase and that immunologically crossreact and/or are homologous to mycobacterial heat shock proteins. A method of the invention involves administering a pharmaceutical composition including at least one peptide to an animal in an amount effective to block or inhibit a pathogenic autoimmune response to central nervous system components. The peptides are useful for the prevention, and treatment of autoimmune inflammatory central nervous system disease.
Inventor(s):	Birnbaum; Gary (Excelsior, MN), Kotilinek; Linda K. (Minneapolis, MN), Braun; Peter Erich (Montreal, Quebec, CA)
Assignee:
Application Number:	08/368,834
Patent Claims:	1. A peptide comprising 9 to 16 amino acids having a sequence of contiguous amino acids from 2',3' cyclic nucleotide 3' phosphodiesterase, wherein the sequence of the peptide is homologous to a peptide sequence of mycobacterial HSP 65 protein (SEQ ID NO:20). 2. A peptide according to claim 1 comprising: a sequence of amino acids 173 to 184 (Seq. ID NO:18) of 2', 3' cyclic nucleotide 3' phosphodiesterase isoform 2. 3. A peptide according to claim 1, having the sequence: Leu-lys-pro-gly-leu-glu-lys-asp-phe (Seq. ID NO:1). 4. A peptide according to claim 1 comprising: a sequence of amino acids 380-396 (Seq. ID NO:3) of 2', 3' cyclic nucleotide 3' phosphodiesterase isoform 2. 5. A peptide according to claim 1 comprising a sequence of amino acids 282-296 (Seq. ID NO:4) of 2', 3' cyclic nucleotide 3' phosphodiesterase isoform 2. 6. A peptide according to claim 1 comprising the sequence of amino acids 64 to 78 (Seq. ID NO:5) of 2', 3' cyclic nucleotide 3' phosphodiesterase isoform 2. 7. A peptide according to claim 1 comprising the sequence of amino acids 328 to 340 (Seq. ID NO:6) of 2', 3' cyclic nucleotide 3' phosphodiesterase isoform 2. 8. A peptide according to claim 1 wherein the peptide has the sequence of amino acids 370 to 385 (Seq. ID NO:8) of 2', 3' cyclic nucleotide 3' phosphodiesterase isoform 2. 9. A peptide according to claim 1 wherein the peptide has a sequence of amino acids 172 to 186 (Seq. ID NO:7) of 2', 3' cyclic nucleotide 3' phosphodiesterase isoform 2. 10. A peptide according to claim 1 wherein the peptide has a sequence of amino acids 335 to 349 (Seq. ID NO:9) of 2', 3' cyclic nucleotide 3' phosphodiesterase. 11. A peptide according to claim 1 further comprising a carrier wherein the peptide is covalently linked to the carrier. 12. A peptide according to claim 11 wherein the carrier is selected from the group consisting of keyhole limpet hemocyanin, bovine serum albumin, human serum albumin and isologous IgG. 13. A peptide comprising from 9 to 16 amino acids having a sequence of contiguous amino acids from 2', 3' cyclic nucleotide 3' phosphodiesterase with from one to five of the amino acids being replaced by a conservative amino acid substitution that increases the degree of homology of the peptide to a homologous peptide sequence of mycobacterial HSP65 protein (SEQ ID NO:20). 14. A peptide comprising from 9 to 16 amino acids having a sequence of contiguous amino acids from mycobacterial HSP65 protein with from one to five of the amino acids being replaced by a conservative amino acid substitution that increases the degree of homology of the peptide to a homologous peptide sequence of 2', 3' cyclic nucleotide 3' phosphodiesterase (SEQ ID NO:20). 15. A peptide comprising 9 to 16 amino acids and having the sequence: Amino acids 173-184 (SEQ ID NO:18) of 2', 3' cyclic nucleotide 3' phosphodiesterase isoform 2; Leu-Lys-Pro-Gly-Leu-Glu-Lys-Asp-Phe (SEQ ID NO: 1); Amino acids 380-396 (SEQ ID NO:3) of 2', 3' cyclic nucleotide 3' phosphodiesterase isoform 2; Amino acids 282-296 (SEQ ID NO:4) of 2', 3' cyclic nucleotide 3' phosphodiesterase isoform 2; Amino acids 64-78 (SEQ ID NO:5) of 2', 3' cyclic nucleotide 3' phosphodiesterase isoform 2; Amino acids 328-340 (SEQ ID NO:6) of 2', 3' cyclic nucleotide 3' phosphodiesterase isoform 2; Amino acids 370-385 (SEQ ID NO:8) of 2', 3' cyclic nucleotide 3' phosphodiesterase isoform 2; Amino acids 172-186 (SEQ ID NO:7) of 2', 3' cyclic nucleotide 3' phosphodiesterase isoform 2; or Amino acids 335-349 (SEQ ID NO:9) of 2', 3' cyclic nucleotide 3' phosphodiesterase.

Details for Patent 5,874,405

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2040-01-28
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2040-01-28
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2040-01-28
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2040-01-28